Revisitando as Síndromas Hipertérmicas Fármaco-Induzidas

Autores

  • Raquel Batista Serviço de Medicina Interna, Centro Hospitalar Médio Tejo, Abrantes, Portugal https://orcid.org/0000-0002-8608-3622
  • Sónia Cunha Martins Serviço de Medicina Interna, Centro Hospitalar Médio Tejo, Abrantes, Portugal
  • Maria de Fátima Pimenta Serviço de Medicina Interna, Centro Hospitalar Médio Tejo, Abrantes, Portugal

DOI:

https://doi.org/10.24950/rspmi/revisao/282/3/2018

Palavras-chave:

Febre, Hipertermia, Preparações Farmacêuticas

Resumo

A febre é uma causa frequente de recorrência aos Serviços de Urgência (SU) mas muitas vezes não está associada a infecção. Existem vários fármacos que, de diferente forma, podem condicionar o sistema de termorregulação causando um estado hipercatabólico que pode ser fatal se não for reconhecido de forma atempada. Existem cinco síndromas hipertérmicas fármaco-induzidas major: (1) síndroma maligna dos neurolépticos, (2) síndromas erotoninérgica, (3) síndroma anticolinérgica, (4) síndroma simpaticomimética e a (5) síndroma da hipertermia maligna. Os autores têm como objectivo a revisão destas síndromas hipertérmicas fármaco-induzidas, o seu diagnóstico diferencial, tratamentos possíveis, bem como os efeitos deletérios de hipertermia sustentada, evidenciando as suas consequências neurológicas. A hipertermia fármaco-induzida é um diagnóstico muitas vezes esquecido aquando a abordagem de quadros febris e cujo tratamento inclui descontinuação do fármaco responsável, medidas de suporte e em alguns casos terapêutica farmacológica adequada.

Downloads

Não há dados estatísticos.

Referências

Walter E, Carraretto M. Drug-induced hyperthermia in critical care. J Intensive Care Soc. 2015; 16: 306-11.

Kaul DR, Flanders SA, Beck JM, Saint S. Brief report: incidence, etiology, risk factor and outcome of hospital-acquired fever: a systematic, evidence- -based review. J Gen Intern Med. 2006; 21:1184-7.

Walter JE, Hanna- Jumma S, Carraretto M, Forni L. The pathophysiological basis and consequences of fever. Crit Care. 2016; 20:200.

Musselman ME, Saely S. Diagnosis and treatment of drug induced hyperthermia. Am J Health-Syst Pharm. 2013; 70: 34-42.

Halloran LL, Bernard DW. Management of drug-induced hyperthermia. Curr Opin Pediatr. 2004; 16:211-5.

Eyer F, Zilker T. Bench-to-bedside review: Mechanisms and management of hyperthermia due to toxicity. Crit Care. 2007;11: 236.

LoVecchio F, Pizon AF, Berrett C, Balls A. Outcomes after enviromental hypertermia. Am J Emerg Med. 2007; 25: 442-4.

Kurz A. Phisiology of termoregulation. Best Pract Res Clin Anesthesiol. 2008; 22:627-44.

Buggy DJ, Crossley AW. Thermoregulation, mild perioperative hypothermia and postanaesthetic shivering. Br J Anaesth. 2000; 84:615-28.

Diaz M, Becker DE. Thermoregulation: physiological and clinical considerations during sedation and general anesthesia. Anesth Prog. 2010; 57:25-32.

O´Grady NP, Barie PS, Barlett JG, Bleck T, Garvey G, Jacobi J, et al. Practice parameters for evaluating new fever in crtically ill adult patients. Task Force of the American College of Critical Care of Medicine of the Society of the Critical Care Medicine in collaboration with the Infectious Disease Society of America. Crit Care Med. 1998; 26:392-408.

Gilman PK. Neuroleptic malignant syndrome: mechanisms, interactions and causality. Mov Disorders. 2010; 25:1780-90.

Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004; 65: 464-70.

Chan-Tack KM. Neuroleptic malignant syndrome due to promethazine. South Med J. 1999; 92:1017-8.

Adnet P, Lestavel P, Krivosic- Horber R. Neuropletic malignant syndrome. Br J Anaesth. 2000; 85:129-35.

Berman BD. Neuroleptic malignant syndrome- a review for neurohospitalists. Neurohospitalist. 2011; 1:41-7.

Keck PE Jr, Carroff SN, McElroy SL. Neuroleptic malignant syndrome and malignant hyperthermia end of controversy? J Neuropsychiatry Clin Neurosci. 1995; 7:135-44.

Levenson JI. Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142:1137-45.

Oruch R, Pryme IF, Engelson BA, Lind A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatry Dis Treat. 2017; 13:161-75.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: APA; 2013.

Caroff SN , Campbell EC, Sullivan KA.Neuroleptic malignant syndrome elderly patients. Expert Rev Neurotherap. 2007; 7:423-31.

Addonizio G , Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. 1987; 22:1004-20.

Isbister GK, Bowe SJ, Dawson A. Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004; 42: 277-85.

McManus P, Mant A, Mitchell PB. Recent trend in the use of antidepressant drugs in Australia. Med J Aust. 2000; 173: 458-61.

Boyer EW, Shannon M. The serotonin syndrome. N Eng J. 2005; 352: 1112-20.

Bijl D. The serotonin syndrome. Neth J Med. 2004; 62:309-13.

Buckley NA, Dawson AH, Ibister GK. Serotonin syndrome. BMJ. 2014; 348: g1626.

Ibister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007; 187: 361-5.

McAllen KJ,Schwartz DR. Adverse drug reactions resulting in hyperthermia in the intensive care unit. Crit Care Med. 2010; 38:S244-52.

Dannawi M. Possible serotonin syndrome after combination of buspirone and St. John´sWort. J Psychopharmacol. 2002; 16:401.

Prator, BC .Serotonin syndrome. J Neurosci Nurs. 2006; 38:102-05.

Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber DA, Bronstein AC, et al. 2005 Annual Report of the American Association of Poison Control Centers national poisoning and exposure database. Clin Toxicol. 2006;44:803–932

Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy. 1999;19:894–6.

Frank, C. Recognition and treatment of serotonin syndrome. Can Fam Physician. 2008; 54:988-92.

Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003; 96: 205-14.

Halloran LL, Bernard DW. Management of drug-induced hyperthermia. Curr Opin Pediatr. 2004; 16:211-5.

Kolecki P, Slabinski MS. Sympathomimetic toxicity-clinical presentation. Medscape 2015[consultado 2017 Nov 10]. Disponível em: https://emedicine.medscape.com/article/818583-clinical#b5

Hadded E, Weinbroum AA, Bem-Abraham R. Drug-induced hyperthermia and muscle rigidity: a pratical approach. Eur J Emerg Med. 2003; 10: 149-54.

Chan TC, Evans SD, Clark RF. Drug-induced hyperthermia. Crit Care Clin. 1997; 13:785-808.

Bohnert AS, Prescott M, Vlahov D, Tardiff KJ, Galea S. Ambient temperature and risk of death of accidental drug overdose in New York, 1990- 2006. Addiction. 2010; 105:1049-54.

Hayes BD, Barrueto FJ. Drug-induced hyperthermic syndromes. Part I.Hyperthermia in Overdose. Emerge Med Clin North Am. 2013; 32:1019-33.

Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review . Orphanet J Rare Dis. 2015; 10:93.

Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from North American malignant registrar of the malignant hyperthermia association of the United States. Anesth Analg. 2014;119:1359-66.

Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007; 2:21.

Schuster F, Johannsen S, Moegele S, Metterlein T, Roewer N, Anestseder M. The effect of succinylocholine on malignant hyperthermia events in susceptible swine. BMC Anestesiology. 2014;14:14.

Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA.A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994; 80: 771-9.

Walter EJ, Carraretto M. The neurological and cognitive consequences of hyperthermia. Crit Care 2016; 20:199.

Labuda A, Cullen N. Brain injury following neuroleptic malignant syndrome: case report and review of literature. Brain Inj. 2006; 20:775-8.

Lee S, Merriam A, Kim TS, Liebling M, Dickson DW, Moore GR. Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic finding and review of literature concerning heat-related nervous syndrome injury. J Neurol Neurosurg Psychiatry. 1989;52:387-91.

Brown T. Clozapine, neuroleptic malignant syndrome, and pancerebellar syndrome. Psychosomatics 1999;40:518-20.

Lal V, Sardana V, Thussu A, Sawhney I, Prabhakar. Cerebellar degeneration following neuropleptic malignant syndrome. Postgrad Med J. 1997; 73: 735-6.

Manto M, Goldman S, Hildebrand J. Cerebellar gait ataxia following neuroleptic malignant syndrome. J Neurol. 1996;243:101-2

Slettedal JK, Nillsen DO, Magelsson M, Loberg EM, Maehlen J. Brain pathology in fatal serotonin syndrome: presentation in two cases. Neuropathology. 2011;27:265-70.

Mustafa S, Elgazzar AH, Essam H, Gopinath S, Matthew M. Hyperthermia alters kidney function and renal scintigraphy. Am J Nephrol. 2007; 2:315-21.

Rosebush P, Stewart T. A prospective analysis of 24 episodes of neurolpetic malignant syndrome. Am J Psychiatry. 1989; 146: 717-25.

Jin Q, Chen E, Jiang J, Lu Y. Acute hepatic failure as a leading manifestation in extertional heat stroke. Case Report Crit Care. 2012;ID295867.

Dematte JE, O´Mara K, Buescher J, Whitney CG, Forsythe S, McNamee T, et al. Near-fatal heat stroke during the 1995 heat wave of Chicago. Ann Intern Med. 1998;129:173-81.

Etulain J, Lapponi MJ, Patruchhi SJ, Romaniuk MA,Benzadón R, Klement GL, et al. Hyperthermia inhibits platelet haemostatic functions and selectively regulates the release of alpha-granule proteins. J Thromb Haemost. 2011; 9:1562-71.

Song XD, Chen AH, Luo BD, Zou F. Pretreatment with aspirin for protection against heat stroke in rats. Di Yi Jun Yi Da Xue Xue Bao. 2004; 24: 631-5.

Strawn JR,Keck PE jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-6.

Sutin KM. Dantrolene sodium. In: Nelson L, Goldfrank LR, editors. Goldfrank´s toxicologic emergencies, 9th ed. New York: McGraw-Hill Medical; 2010. p.1001-2.

Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology. 1982; 56:254-62.

Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13:100-9.

Howland MA.Physostigmine salicylate:antidote in depth. In: Nelson L, Goldfrank LR, editors. Goldfrank´s toxicologic emergencies, 9th ed. New York: McGraw-Hill Medical:2010. p. 435-42.

Downloads

Publicado

01-04-2022

Como Citar

1.
Batista R, Cunha Martins S, Pimenta M de F. Revisitando as Síndromas Hipertérmicas Fármaco-Induzidas. RPMI [Internet]. 1 de Abril de 2022 [citado 29 de Março de 2024];25(3):224-32. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/483

Edição

Secção

Artigos de Revisão

Artigos mais lidos do(s) mesmo(s) autor(es)